{"entries": [{"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-acts-protect-children-unapproved-fluoride-drug-products", "title": "FDA Acts to Protect Children from Unapproved Fluoride Drug Products", "abstract": "The U.S. Food and Drug Administration today announced actions to restrict the sale of unapproved ingestible fluoride prescription drug products for children.", "url": "http://www.fda.gov/news-events/press-announcements/fda-acts-protect-children-unapproved-fluoride-drug-products", "published_date": "2025-10-31", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-moves-accelerate-biosimilar-development-and-lower-drug-costs", "title": "FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs", "abstract": "The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.", "url": "http://www.fda.gov/news-events/press-announcements/fda-moves-accelerate-biosimilar-development-and-lower-drug-costs", "published_date": "2025-10-29", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-new-world-screwworm-drug-dogs", "title": "FDA Issues Emergency Use Authorization for New World Screwworm Drug for Dogs", "abstract": "FDA issued an Emergency Use Authorization (EUA) concluding that based on the scientific evidence available, Credelio (lotilaner) chewable tablets may be effective in treating New World screwworm (NWS) infestations in dogs and puppies.", "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-new-world-screwworm-drug-dogs", "published_date": "2025-10-24", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-publishes-filing-checklists-prevent-submission-delays", "title": "FDA Publishes Filing Checklists to Prevent Submission Delays", "abstract": "The U.S. Food and Drug Administration today made public filing checklists used internally by Center for Drug Evaluation and Research (CDER) staff to determine if a submitted application is complete and reviewable.", "url": "http://www.fda.gov/news-events/press-announcements/fda-publishes-filing-checklists-prevent-submission-delays", "published_date": "2025-10-23", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors", "title": "FDA Awards First-Ever National Priority Vouchers to Nine Sponsors", "abstract": "The U.S. Food and Drug Administration today announced 9 voucher recipients under the new Commissioner’s National Priority Voucher (CNPV) pilot program.", "url": "http://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors", "published_date": "2025-10-16", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-conditionally-approves-first-drug-prevention-and-treatment-new-world-screwworm-infestations", "title": "FDA Conditionally Approves First Drug for Prevention and Treatment of New World Screwworm Infestations in Cattle", "abstract": "The U.S. Food and Drug Administration conditionally approved Dectomax-CA1 (doramectin injection) injectable solution for the prevention and treatment of New World screwworm larval infestations, and prevention of NWS reinfestation for 21 days.", "url": "http://www.fda.gov/news-events/press-announcements/fda-conditionally-approves-first-drug-prevention-and-treatment-new-world-screwworm-infestations", "published_date": "2025-09-30", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-encouraging-retailers-stop-selling-illegal-vapes", "title": "A Statement From FDA Commissioner Marty Makary, M.D., M.P.H.: Encouraging Retailers to Stop Selling Illegal Vapes", "abstract": "As part of the FDA’s broader strategy to combat the crisis of youth vaping, we are launching an initiative to increase voluntary compliance from retailers.", "url": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-encouraging-retailers-stop-selling-illegal-vapes", "published_date": "2025-09-30", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia", "title": "FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia", "abstract": "Today, the U.S. Food and Drug Administration authorized marketing of the Essilor Stellest eyeglass lenses to correct myopia, commonly referred to as nearsightedness, with or without astigmatism and to slow the progression of the disease in children 6 to 12 years old at the initiation of treatment.", "url": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia", "published_date": "2025-09-25", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-removes-risk-evaluation-and-mitigation-strategies-rems-caprelsa-vandetanib", "title": "FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib)", "abstract": "The U.S. Food and Drug Administration today announced that it has eliminated special safety requirements to monitor for serious heart rhythm problems in patients taking Caprelsa (vandetanib), an approved cancer medication made by Genzyme Corporation.", "url": "http://www.fda.gov/news-events/press-announcements/fda-removes-risk-evaluation-and-mitigation-strategies-rems-caprelsa-vandetanib", "published_date": "2025-09-25", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy", "title": "FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy", "abstract": "The U.S. Food and Drug Administration today initiated the process for a label change for acetaminophen (Tylenol and similar products) to reflect evidence suggesting that the use of acetaminophen by pregnant women may be associated with an increased risk of neurological conditions such as autism and", "url": "http://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy", "published_date": "2025-09-22", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms", "title": "FDA Takes Action to Make a Treatment Available for Autism Symptoms", "abstract": "The U.S. Food and Drug Administration today initiated the approval of leucovorin calcium tablets for patients with cerebral folate deficiency (CFD), a neurological condition that affects folate (a vitamin essential for brain health) transport into the brain.", "url": "http://www.fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms", "published_date": "2025-09-22", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome", "title": "FDA Grants Accelerated Approval to First Treatment for Barth Syndrome", "abstract": "The U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome, in patients weighing at least 30 kg.", "url": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome", "published_date": "2025-09-19", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-launches-real-time-adverse-event-reporting-dashboard-cosmetic-products", "title": "FDA Launches Real-Time Adverse Event Reporting Dashboard for Cosmetic Products", "abstract": "The U.S. Food and Drug Administration today announced the launch of the FDA Adverse Event Reporting System (FAERS) Public Dashboard for Cosmetic Products, an interactive tool designed to facilitate the public’s ability to query real-time adverse event data on cosmetic products.", "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-real-time-adverse-event-reporting-dashboard-cosmetic-products", "published_date": "2025-09-12", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/hhs-cbp-seize-865-million-worth-illegal-e-cigarettes-largest-ever-operation", "title": "HHS, CBP Seize $86.5 Million Worth of Illegal E-Cigarettes in Largest-Ever Operation", "abstract": "The U.S. Department of Health and Human Services (HHS), through the U.S. Food and Drug Administration (FDA), and U.S. Customs and Border Protection (CBP) today announced the seizure of 4.7 million units of unauthorized e-cigarette products with an estimated retail value of $86.5 million – the larges", "url": "http://www.fda.gov/news-events/press-announcements/hhs-cbp-seize-865-million-worth-illegal-e-cigarettes-largest-ever-operation", "published_date": "2025-09-10", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-issues-new-guidance-expand-non-opioid-options-chronic-pain-curb-misuse", "title": "FDA Issues New Guidance to Expand Non-Opioid Options for Chronic Pain, Curb Misuse", "abstract": "As part of its broader strategy to address the opioid crisis, the U.S. Food and Drug Administration today issued draft guidance titled “Development of Non-Opioid Analgesics for Chronic Pain” to accelerate safe and effective non-opioid treatments and to reduce prescription-related opioid misuse.", "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-new-guidance-expand-non-opioid-options-chronic-pain-curb-misuse", "published_date": "2025-09-10", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising", "title": "FDA Launches Crackdown on Deceptive Drug Advertising", "abstract": "The U.S. Department of Health and Human Services and the Food and Drug Administration today announced sweeping reforms to rein in misleading direct-to-consumer pharmaceutical advertisements.", "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising", "published_date": "2025-09-09", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children", "title": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children", "abstract": "The U.S. Food and Drug Administration today approved expanded use of Vonvendi [von Willebrand factor (Recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease (VWD) and on-demand and treatment of bleeding episodes and perio", "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children", "published_date": "2025-09-05", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients", "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients", "abstract": "The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.", "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients", "published_date": "2025-09-05", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89", "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89", "abstract": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.", "url": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89", "published_date": "2025-09-04", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/news-events/press-announcements/fda-advances-rare-disease-drug-development-new-evidence-principles", "title": "FDA Advances Rare Disease Drug Development with New Evidence Principles", "abstract": "FDA advanced Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability for the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.", "url": "http://www.fda.gov/news-events/press-announcements/fda-advances-rare-disease-drug-development-new-evidence-principles", "published_date": "2025-09-03", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/olympus-issues-voluntary-labeling-update-bronchoscopes-used-laser-therapy-equipment", "title": "Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment", "abstract": "CENTER VALLEY, Pa., (October 31, 2025) – Olympus Corporation has announced a voluntary, global medical device corrective action to provide further clarification on the safe and effective use of bronchoscopes with laser therapy, argon plasma coagulation or high-frequency cauterization equipment durin", "url": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/olympus-issues-voluntary-labeling-update-bronchoscopes-used-laser-therapy-equipment", "published_date": "2025-11-03", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-20-meq-potassium-chloride-injection-due", "title": "Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 20 mEq Potassium Chloride Injection Due To Overwrap Mislabeled As 10 mEq Potassium Chloride Injection", "abstract": "FOR IMMEDIATE RELEASE – October 31, 2025 AUSTIN, TX – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABELLED lot of POTASSIUM CHLORIDE Inj. 20 mEq, NDC 0990-7077-14. The OVERWRAP label of lot 1030613, Expiration Date: 09-30-2026 may incorrectly identify the product", "url": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-20-meq-potassium-chloride-injection-due", "published_date": "2025-11-03", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/safety-communications/hintermann-series-h3-total-ankle-replacement-has-higher-expected-risk-device-failure-fda-safety", "title": "Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication", "abstract": "Learn more about recommendations for patients who are considering a Hintermann Series H3 TAR system or who have one; recommendations for health care providers.", "url": "http://www.fda.gov/medical-devices/safety-communications/hintermann-series-h3-total-ankle-replacement-has-higher-expected-risk-device-failure-fda-safety", "published_date": "2025-10-31", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication", "title": "Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication", "abstract": "FDA is aware of serious complications reported with certain uses of radiofrequency microneedling devices; asks for reports of injuries related these devices", "url": "http://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication", "published_date": "2025-10-15", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/safety/medical-product-safety-information/fda-approves-labeling-changes-include-boxed-warning-immune-effector-cell-associated-enterocolitis", "title": "FDA Approves Labeling Changes that Include a Boxed Warning for Immune Effector Cell-associated Enterocolitis Following Treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.)", "abstract": "The FDA has received reports of immune effector cell-associated enterocolitis (IEC-EC) in patients who received treatment with CARVYKTI.", "url": "http://www.fda.gov/safety/medical-product-safety-information/fda-approves-labeling-changes-include-boxed-warning-immune-effector-cell-associated-enterocolitis", "published_date": "2025-10-10", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/alert-automated-impella-controller-correction-due-cybersecurity-issue-abiomed", "title": "Alert: Automated Impella Controller Correction due to Cybersecurity Issue from Abiomed", "abstract": "Abiomed has issued a letter to affected customers of cybersecurity vulnerabilities related to the operating system in the Automated Impella Controller", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/alert-automated-impella-controller-correction-due-cybersecurity-issue-abiomed", "published_date": "2025-10-10", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/trividia-health-inc-initiates-voluntary-recall-limited-number-true-metrixr-blood-glucose-meters", "title": "Trividia Health, Inc. Initiates Voluntary Recall of Limited Number of TRUE METRIX® Blood Glucose Meters", "abstract": "(FT. LAUDERDALE, FL) –October 7, 2025 – Trividia Health, Inc., announced today that it is initiating a voluntary recall of a limited number of TRUE METRIX® Self-Monitoring Blood glucose meters co-branded under the Good Neighbor Pharmacy® brand and distributed in the United States.", "url": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/trividia-health-inc-initiates-voluntary-recall-limited-number-true-metrixr-blood-glucose-meters", "published_date": "2025-10-07", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/endoscopic-aspiration-needle-recall-olympus-removes-certain-vizishot-2-flex-19g-needles-due", "title": "Endoscopic Aspiration Needle Recall: Olympus Removes Certain ViziShot 2 FLEX (19G) Needles Due to Potentially Deformed A-traumatic Tips", "abstract": "Certain lots of ViziShot 2 FLEX (19G) aspiration needles may have deformed a-traumatic tips that pose a risk to patient safety if they are used.", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/endoscopic-aspiration-needle-recall-olympus-removes-certain-vizishot-2-flex-19g-needles-due", "published_date": "2025-09-30", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-medical-device-recall", "title": "What is a Medical Device Recall?", "abstract": "What is a Medical Device Recall?", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-medical-device-recall", "published_date": "2025-09-29", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-early-alert", "title": "What is an Early Alert?", "abstract": "Early Alerts minimize time between FDA’s initial awareness of a potentially high-risk medical device removal or correction and FDA’s public communication", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-early-alert", "published_date": "2025-09-29", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/recall-and-alert-resources", "title": "Recall and Alert Resources", "abstract": ".This page includes a list of various resources offered by the FDA regarding recalls and alerts for medical devices<br />\n  <br />", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/recall-and-alert-resources", "published_date": "2025-09-29", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-infusion-set-performance-issue-bd", "title": "Update on Alert: Infusion Set Performance Issue from BD", "abstract": "This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program.", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-infusion-set-performance-issue-bd", "published_date": "2025-09-29", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/blood-and-plasma-warming-device-correction-3m-company-issues-correction-ranger-bloodfluid-warming", "title": "Blood and Plasma Warming Device Correction: 3M Company Issues Correction for Ranger Blood/Fluid Warming System", "abstract": "3M is correcting their Ranger Blood/Fluid Warming System due to incomplete temperature and flow rate specifications on the label.", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/blood-and-plasma-warming-device-correction-3m-company-issues-correction-ranger-bloodfluid-warming", "published_date": "2025-09-24", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-automated-impella-controller-purge-retainer-fixation-issue-abiomed", "title": "Early Alert: Automated Impella Controller Purge Retainer Fixation Issue from Abiomed", "abstract": "FDA is announcing an Early Alert for Abiomed’s Automated Impella Controller due to Purge Pressure Issues", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-automated-impella-controller-purge-retainer-fixation-issue-abiomed", "published_date": "2025-09-23", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/olympus-issues-voluntary-recall-specific-lots-vizishot-2-flex-19g-ebus-tbna-needles", "title": "Olympus Issues Voluntary Recall for Specific Lots of ViziShot 2 FLEX (19G) EBUS -TBNA Needles", "abstract": "CENTER VALLEY, Pa., (September 19, 2025) — Olympus Corporation has announced a voluntary, global medical device removal action for ViziShot 2 FLEX (19G) EBUS -TBNA needles (“ViziShot 2 FLEX”) manufactured prior to May 12, 2025, after receiving reports of device components detaching during procedures", "url": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/olympus-issues-voluntary-recall-specific-lots-vizishot-2-flex-19g-ebus-tbna-needles", "published_date": "2025-09-22", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-tactiflex-ablation-catheter-issue-abbott", "title": "Early Alert: TactiFlex Ablation Catheter Issue from Abbott", "abstract": "Abbott has issued new instructions on removing TactiFlex Ablation Catheter, Sensor Enabled from its packaging due to tip detachment issues", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-tactiflex-ablation-catheter-issue-abbott", "published_date": "2025-09-18", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/safety/medical-product-safety-information/fda-updates-warning-about-imported-cookware-may-leach-lead-august-2025", "title": "FDA Updates Warning About Imported Cookware That May Leach Lead: August 2025", "abstract": "FDA Updates Warning About Imported Cookware That May Leach Lead: August 2025. Retailers Should Not Sell and Consumers Should Not Use Certain Cookware Because of Their Potential to Leach Lead into Food When Cooking", "url": "http://www.fda.gov/safety/medical-product-safety-information/fda-updates-warning-about-imported-cookware-may-leach-lead-august-2025", "published_date": "2025-09-17", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/safety-communications/do-not-use-unauthorized-infant-devices-monitoring-vital-signs-fda-safety-communication", "title": "Do Not Use Unauthorized Infant Devices for Monitoring Vital Signs: FDA Safety Communication", "abstract": "FDA alerts of risks with use of unauthorized infant monitoring devices, which have not been reviewed for safety and effectiveness.", "url": "http://www.fda.gov/medical-devices/safety-communications/do-not-use-unauthorized-infant-devices-monitoring-vital-signs-fda-safety-communication", "published_date": "2025-09-16", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/safety-communications/do-not-use-unauthorized-devices-measuring-blood-pressure-fda-safety-communication", "title": "Do Not Use Unauthorized Devices for Measuring Blood Pressure: FDA Safety Communication", "abstract": "FDA alerts of risks with use of unauthorized blood pressure devices, which have not been reviewed for safety and effectiveness.", "url": "http://www.fda.gov/medical-devices/safety-communications/do-not-use-unauthorized-devices-measuring-blood-pressure-fda-safety-communication", "published_date": "2025-09-16", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "fda", "source_id": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/electrical-wheelchair-component-correction-mo-vis-bvba-issues-correction-r-net-joysticks-due", "title": "Electrical Wheelchair Component Correction: mo-Vis BVBA Issues Correction for R-net Joysticks Due to a Firmware Error", "abstract": "mo-Vis BVBA is correcting R-net Joysticks due to a firmware error that may cause the wheelchair to ignore the neutral setting and move unexpectedly.", "url": "http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/electrical-wheelchair-component-correction-mo-vis-bvba-issues-correction-r-net-joysticks-due", "published_date": "2025-09-16", "authors": [{"name": "FDA"}], "journal_or_venue": "FDA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["US"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}]}